Trastuzumab plus chemotherapy is an effective therapy in HER2 positive advanced gastric
cancer (AGC). However, the efficacy of routine trastuzumab therapy and its association with
clinicopathologic factors remain unclear. The object of the study is to determine whether the
addition of trastuzumab to first-line chemotherapy improves efficacy compared with
chemotherapy alone in HER2 positive AGC.